LRRK2 and Parkinson disease.

OBJECTIVES To review the molecular genetics and functional biology of leucine-rich repeat kinase 2 (LRRK2) in parkinsonism and to summarize the opportunities and challenges to develop interventions for Parkinson disease (PD) based on this genetic insight. DATA SOURCES Publications cited are focused on LRRK2 biology between 2004 and March 2009. STUDY SELECTION Literature selected was based on original contributions, seminal observations, and thoughtful reviews. DATA EXTRACTION Unless stated otherwise, data was primarily abstracted from peer-reviewed literature appearing on PubMed. DATA SYNTHESIS Genetic mutations that predispose PD are diagnostically useful in early or atypical presentations. The molecular pathways identified suggest therapeutic interventions for Lrrk2 and idiopathic PD and the rationale and opportunity to develop physiologically relevant biomarkers and experimental models with which to test them. CONCLUSIONS Both affected and asymptomatic LRRK2 carriers now provide the opportunity to define the natural history of PD. This includes the frequency, penetrance, and rate of motor symptoms, nonmotor comorbidities, and their associated biomarkers.

[1]  D. Dickson,et al.  Leucine-Rich Repeat Kinase 2 Gene-Associated Disease: Redefining Genotype-Phenotype Correlation , 2010, Neurodegenerative Diseases.

[2]  J. Buxbaum,et al.  Enhanced Striatal Dopamine Transmission and Motor Performance with LRRK2 Overexpression in Mice Is Eliminated by Familial Parkinson's Disease Mutation G2019S , 2010, The Journal of Neuroscience.

[3]  H. Cai,et al.  Leucine-Rich Repeat Kinase 2 Regulates the Progression of Neuropathology Induced by Parkinson's-Disease-Related Mutant α-synuclein , 2009, Neuron.

[4]  H. Cai,et al.  Phosphorylation of Ezrin/Radixin/Moesin Proteins by LRRK2 Promotes the Rearrangement of Actin Cytoskeleton in Neuronal Morphogenesis , 2009, The Journal of Neuroscience.

[5]  F. Gillardon.  Interaction of elongation factor 1-alpha with leucine-rich repeat kinase 2 impairs kinase activity and microtubule bundling in vitro , 2009, Neuroscience.

[6]  Yih-Ru Wu,et al.  LRRK2 G2385R modulates age at onset in Parkinson's disease: A multi‐center pooled analysis , 2009, American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics.

[7]  F. Gillardon.  Leucine‐rich repeat kinase 2 phosphorylates brain tubulin‐beta isoforms and modulates microtubule stability – a point of convergence in Parkinsonian neurodegeneration? , 2009, Journal of neurochemistry.

[8]  A. Pisani,et al.  R1441C mutation in LRRK2 impairs dopaminergic neurotransmission in mice , 2009, Proceedings of the National Academy of Sciences.

[9]  M. Farrer,et al.  Haplotype analysis of Lrrk2 R1441H carriers with parkinsonism. , 2009, Parkinsonism & related disorders.

[10]  R. Burke,et al.  Mutant LRRK2R1441G BAC transgenic mice recapitulate cardinal features of Parkinson's disease , 2009, Nature Neuroscience.

[11]  S. Eimer,et al.  Caenorhabditits elegans LRK-1 and PINK-1 Act Antagonistically in Stress Response and Neurite Outgrowth* , 2009, The Journal of Biological Chemistry.

[12]  L. Petrucelli,et al.  CHIP regulates leucine-rich repeat kinase-2 ubiquitination, degradation, and toxicity , 2009, Proceedings of the National Academy of Sciences.

[13]  W. Dauer,et al.  The Parkinson Disease Protein Leucine-Rich Repeat Kinase 2 Transduces Death Signals via Fas-Associated Protein with Death Domain and Caspase-8 in a Cellular Model of Neurodegeneration , 2009, The Journal of Neuroscience.

[14]  B. Giasson,et al.  Identification of compounds that inhibit the kinase activity of leucine-rich repeat kinase 2. , 2009, Biochemical and biophysical research communications.

[15]  E. Waxman,et al.  Clinical and pathological characteristics of patients with Leucine‐rich repeat kinase‐2 mutations , 2009, Movement disorders : official journal of the Movement Disorder Society.

[16]  E. Brown,et al.  Investigation of leucine‐rich repeat kinase 2 , 2009, The FEBS journal.

[17]  N. Pedersen,et al.  Complete ascertainment of Parkinson disease in the Swedish Twin Registry , 2008, Neurobiology of Aging.

[18]  V. Sossi,et al.  Progression of dopaminergic dysfunction in a LRRK2 kindred , 2008, Neurology.

[19]  P. V. van Haastert,et al.  Intramolecular Activation Mechanism of the Dictyostelium LRRK2 Homolog Roco Protein GbpC* , 2008, Journal of Biological Chemistry.

[20]  H. Melrose.  Update on the functional biology of Lrrk2. , 2008, Future neurology.

[21]  J. Holton,et al.  Hyposmia in G2019S LRRK2-related parkinsonism , 2008, Neurology.

[22]  R. Takahashi,et al.  Phosphorylation of 4E‐BP by LRRK2 affects the maintenance of dopaminergic neurons in Drosophila , 2008, The EMBO journal.

[23]  Yi Zhao,et al.  LRRK2 R1628P increases risk of Parkinson’s disease: replication evidence , 2008, Human Genetics.

[24]  A. Wittinghofer,et al.  Structure of the Roc–COR domain tandem of C. tepidum, a prokaryotic homologue of the human LRRK2 Parkinson kinase , 2008, The EMBO journal.

[25]  Y. Sohn,et al.  Analysis of PARK genes in a Korean cohort of early-onset Parkinson disease , 2008, Neurogenetics.

[26]  P. Matthews,et al.  LRRK2 Gly2019Ser penetrance in Arab–Berber patients from Tunisia: a case-control genetic study , 2008, The Lancet Neurology.

[27]  E. Tolosa,et al.  Phenotype, genotype, and worldwide genetic penetrance of LRRK2-associated Parkinson's disease: a case-control study , 2008, The Lancet Neurology.

[28]  M. Farrer,et al.  Analysis of Lrrk2 R1628P as a risk factor for Parkinson's disease , 2008, Annals of neurology.

[29]  M. Cookson,et al.  The Parkinson Disease-associated Leucine-rich Repeat Kinase 2 (LRRK2) Is a Dimer That Undergoes Intramolecular Autophosphorylation* , 2008, Journal of Biological Chemistry.

[30]  M. Farrer,et al.  LRRK2 mutation in familial Parkinson's disease in a Taiwanese population: clinical, PET, and functional studies. , 2008, Journal of biomedical science.

[31]  Xinglong Wang,et al.  The Roc domain of leucine‐rich repeat kinase 2 is sufficient for interaction with microtubules , 2008, Journal of neuroscience research.

[32]  C. Chu,et al.  Role of autophagy in G2019S‐LRRK2‐associated neurite shortening in differentiated SH‐SY5Y cells , 2008, Journal of neurochemistry.

[33]  M. Farrer,et al.  Lrrk2 R1441C parkinsonism is clinically similar to sporadic Parkinson diseaseSYMBOL , 2008, Neurology.

[34]  H. Cai,et al.  The Chaperone Activity of Heat Shock Protein 90 Is Critical for Maintaining the Stability of Leucine-Rich Repeat Kinase 2 , 2008, The Journal of Neuroscience.

[35]  Maria D. Guillily,et al.  Investigating Convergent Actions of Genes Linked to Familial Parkinson’s Disease , 2008, Neurodegenerative Diseases.

[36]  C. Ross,et al.  A Drosophila model for LRRK2-linked parkinsonism , 2008, Proceedings of the National Academy of Sciences.

[37]  M. Cookson,et al.  Structure of the ROC domain from the Parkinson's disease-associated leucine-rich repeat kinase 2 reveals a dimeric GTPase , 2008, Proceedings of the National Academy of Sciences.

[38]  S. Poths,et al.  RNA interference of LRRK2–microarray expression analysis of a Parkinson’s disease key player , 2008, Neurogenetics.

[39]  R. Bodmer,et al.  Dispensable role of Drosophila ortholog of LRRK2 kinase activity in survival of dopaminergic neurons , 2008, Molecular Neurodegeneration.

[40]  M. Farrer,et al.  Lrrk2-associated parkinsonism is a major cause of disease in Northern Spain. , 2007, Parkinsonism & related disorders.

[41]  T. Dawson,et al.  Dynamic and redundant regulation of LRRK2 and LRRK1 expression , 2007, BMC Neuroscience.

[42]  M. Cookson,et al.  The Roles of Kinases in Familial Parkinson's Disease , 2007, The Journal of Neuroscience.

[43]  T. Foroud,et al.  LRRK2 mutation analysis in Parkinson disease families with evidence of linkage to PARK8 , 2007, Neurology.

[44]  H. Braak,et al.  Parkinson's disease: a dual‐hit hypothesis , 2007, Neuropathology and applied neurobiology.

[45]  Nir Giladi,et al.  The LRRK2 G2019S mutation in Ashkenazi Jews with Parkinson disease , 2007, Neurology.

[46]  Shu G. Chen,et al.  The Parkinson's disease-associated protein, leucine-rich repeat kinase 2 (LRRK2), is an authentic GTPase that stimulates kinase activity. , 2007, Experimental cell research.

[47]  L. Petrucelli,et al.  Identification of potential protein interactors of Lrrk2. , 2007, Parkinsonism & related disorders.

[48]  C. Olanow,et al.  Leucine‐rich repeat kinase 2 (LRRK2)/PARK8 possesses GTPase activity that is altered in familial Parkinson’s disease R1441C/G mutants , 2007, Journal of neurochemistry.

[49]  Asunción Delgado,et al.  Mechanistic insight into the dominant mode of the Parkinson's disease-associated G2019S LRRK2 mutation. , 2007, Human molecular genetics.

[50]  R. Nichols,et al.  LRRK2 phosphorylates moesin at threonine-558: characterization of how Parkinson's disease mutants affect kinase activity. , 2007, The Biochemical journal.

[51]  David I. Bass,et al.  A comparative analysis of leucine-rich repeat kinase 2 (Lrrk2) expression in mouse brain and Lewy body disease , 2007, Neuroscience.

[52]  Jongkyeong Chung,et al.  Loss of LRRK2/PARK8 induces degeneration of dopaminergic neurons in Drosophila. , 2007, Biochemical and biophysical research communications.

[53]  P. Emson,et al.  Localization of Parkinson’s disease-associated LRRK2 in normal and pathological human brain , 2007, Brain Research.

[54]  M. Cookson,et al.  The R1441C mutation of LRRK2 disrupts GTP hydrolysis. , 2007, Biochemical and biophysical research communications.

[55]  R. Burke.  Inhibition of mitogen-activated protein kinase and stimulation of Akt kinase signaling pathways: Two approaches with therapeutic potential in the treatment of neurodegenerative disease. , 2007, Pharmacology & therapeutics.

[56]  P. Barone,et al.  Apoptotic mechanisms in mutant LRRK2-mediated cell death. , 2007, Human molecular genetics.

[57]  M. Therrien,et al.  KSR and CNK: two scaffolds regulating RAS-mediated RAF activation , 2007, Oncogene.

[58]  Mathias Toft,et al.  MAPK‐pathway activity, Lrrk2 G2019S, and Parkinson's disease , 2007, Journal of neuroscience research.

[59]  G. Pezzoli,et al.  Evaluation of LRRK2 G2019S penetrance , 2007, Neurology.

[60]  Naoki Hisamoto,et al.  LRK-1, a C. elegans PARK8-Related Kinase, Regulates Axonal-Dendritic Polarity of SV Proteins , 2007, Current Biology.

[61]  M. Farrer,et al.  Lrrk2 G2385R is an ancestral risk factor for Parkinson's disease in Asia. , 2007, Parkinsonism & related disorders.

[62]  N. Hattori,et al.  Leucine-Rich Repeat kinase 2 G2385R variant is a risk factor for Parkinson disease in Asian population , 2007, Neuroreport.

[63]  K. Lim,et al.  Parkinson's disease-associated mutations in LRRK2 link enhanced GTP-binding and kinase activities to neuronal toxicity. , 2007, Human molecular genetics.

[64]  T. Katada,et al.  GTP binding is essential to the protein kinase activity of LRRK2, a causative gene product for familial Parkinson's disease. , 2007, Biochemistry.

[65]  E. Tolosa,et al.  G2019S LRRK2 mutation causing Parkinson’s disease without Lewy bodies , 2007, Journal of Neurology, Neurosurgery & Psychiatry.

[66]  P. Emson,et al.  Expression and localization of Parkinson's disease‐associated leucine‐rich repeat kinase 2 in the mouse brain , 2007, Journal of neurochemistry.

[67]  J. Jankovic,et al.  Screening for Lrrk2 G2019S and clinical comparison of Tunisian and North American Caucasian Parkinson's disease families , 2007, Movement disorders : official journal of the Movement Disorder Society.

[68]  M. Farrer,et al.  Leucine-rich repeat kinase 1: a paralog of LRRK2 and a candidate gene for Parkinson’s disease , 2007, Neurogenetics.

[69]  M. Farrer,et al.  Anatomical localization of leucine-rich repeat kinase 2 in mouse brain , 2006, Neuroscience.

[70]  A. Singleton,et al.  A common genetic factor for Parkinson disease in ethnic Chinese population in Taiwan , 2006, BMC neurology.

[71]  Matthew J. Farrer,et al.  Digenic parkinsonism: Investigation of the synergistic effects of PRKN and LRRK2 , 2006, Neuroscience Letters.

[72]  I. Marín.  The Parkinson disease gene LRRK2: evolutionary and structural insights. , 2006, Molecular biology and evolution.

[73]  K. Marder,et al.  Frequency of LRRK2 mutations in early- and late-onset Parkinson disease , 2006, Neurology.

[74]  A. Abeliovich,et al.  The Familial Parkinsonism Gene LRRK2 Regulates Neurite Process Morphology , 2006, Neuron.

[75]  A. Singleton,et al.  Parkinson's disease due to the R1441G mutation in Dardarin: A founder effect in the basques , 2006, Movement disorders : official journal of the Movement Disorder Society.

[76]  P. Emson,et al.  Localization of LRRK2 to membranous and vesicular structures in mammalian brain , 2006, Annals of neurology.

[77]  E. Tan.  Identification of a common genetic risk variant (LRRK2 Gly2385Arg) in Parkinson's disease. , 2006, Annals of the Academy of Medicine, Singapore.

[78]  M. Farrer,et al.  Parkinsonism, Lrrk2 G2019S, and tau neuropathology , 2006, Neurology.

[79]  J. Nutt,et al.  Validity and utility of a LRRK2 G2019S mutation test for the diagnosis of Parkinson's disease. , 2006, Genetic testing.

[80]  J. Nutt,et al.  LRRK2 G2019S in families with Parkinson disease who originated from Europe and the Middle East: evidence of two distinct founding events beginning two millennia ago. , 2006, American journal of human genetics.

[81]  J. Hardy,et al.  No definitive evidence for a role for the environment in the etiology of Parkinson's Disease , 2006, Movement disorders : official journal of the Movement Disorder Society.

[82]  P. Silburn,et al.  Parkinson's disease and family history. , 2006, Parkinsonism & related disorders.

[83]  Tetsuaki Arai,et al.  LRRK2 Expression in Normal and Pathologic Human Brain and in Human Cell Lines , 2006, Journal of neuropathology and experimental neurology.

[84]  C. Ross,et al.  Kinase activity of mutant LRRK2 mediates neuronal toxicity , 2006, Nature Neuroscience.

[85]  M. Farrer,et al.  Clinical features of Parkinson disease patients with homozygous leucine-rich repeat kinase 2 G2019S mutations. , 2006, Archives of neurology.

[86]  David W. Miller,et al.  Kinase activity is required for the toxic effects of mutant LRRK2/dardarin , 2006, Neurobiology of Disease.

[87]  M. Farrer,et al.  Clinicogenetic study of mutations in LRRK2 exon 41 in Parkinson's disease patients from 18 countries , 2006, Movement disorders : official journal of the Movement Disorder Society.

[88]  M. Breteler,et al.  Epidemiology of Parkinson's disease , 2006, The Lancet Neurology.

[89]  Matthew J. Farrer,et al.  LRRK2 in Parkinson's disease: protein domains and functional insights , 2006, Trends in Neurosciences.

[90]  D. Schaid,et al.  Complex segregation analysis of Parkinson's disease: The Mayo Clinic Family Study , 2006, Annals of neurology.

[91]  B. Oostra,et al.  A common missense variant in the LRRK2 gene, Gly2385Arg, associated with Parkinson’s disease risk in Taiwan , 2006, Neurogenetics.

[92]  M. Farrer,et al.  LRRK2 mutations are a common cause of Parkinson's disease in Spain , 2006, European journal of neurology.

[93]  M. Farrer.  Genetics of Parkinson disease: paradigm shifts and future prospects , 2006, Nature Reviews Genetics.

[94]  R. Marconi,et al.  Comprehensive analysis of the LRRK2 gene in sixty families with Parkinson's disease , 2006, European Journal of Human Genetics.

[95]  Irene Litvan,et al.  Lrrk2 and Lewy body disease , 2006, Annals of neurology.

[96]  M. Farrer,et al.  LRRK2: a common pathway for parkinsonism, pathogenesis and prevention? , 2006, Trends in molecular medicine.

[97]  J. Trojanowski,et al.  Biochemical and pathological characterization of Lrrk2 , 2006, Annals of neurology.

[98]  P. Pollak,et al.  LRRK2 G2019S as a cause of Parkinson's disease in North African Arabs. , 2006, The New England journal of medicine.

[99]  Christine Klein,et al.  LRRK2 G2019S as a cause of Parkinson's disease in Ashkenazi Jews. , 2006, The New England journal of medicine.

[100]  T. Meitinger,et al.  The Parkinson disease causing LRRK2 mutation I2020T is associated with increased kinase activity. , 2006, Human molecular genetics.

[101]  Andrew B West,et al.  Leucine-rich repeat kinase 2 (LRRK2) interacts with parkin, and mutant LRRK2 induces neuronal degeneration. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[102]  Vesna Sossi,et al.  PET in LRRK2 mutations: comparison to sporadic Parkinson's disease and evidence for presymptomatic compensation. , 2005, Brain : a journal of neurology.

[103]  A. Singleton,et al.  Mutations in the gene LRRK2 encoding dardarin (PARK8) cause familial Parkinson's disease: clinical, pathological, olfactory and functional imaging and genetic data. , 2005, Brain : a journal of neurology.

[104]  C. Ross,et al.  Parkinson's disease-associated mutations in leucine-rich repeat kinase 2 augment kinase activity. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[105]  M. Canesi,et al.  The G6055A (G2019S) mutation in LRRK2 is frequent in both early and late onset Parkinson’s disease and originates from a common ancestor , 2005, Journal of Medical Genetics.

[106]  M. Farrer,et al.  Lrrk2 pathogenic substitutions in Parkinson's disease , 2005, Neurogenetics.

[107]  H. Payami,et al.  Escaping Parkinson's disease: A neurologically healthy octogenarian with the LRRK2 G2019S mutation , 2005, Movement disorders : official journal of the Movement Disorder Society.

[108]  A. Dürr,et al.  LRRK2 haplotype analyses in European and North African families with Parkinson disease: a common founder for the G2019S mutation dating from the 13th century. , 2005, American journal of human genetics.

[109]  Kazuko Hasegawa,et al.  An LRRK2 mutation as a cause for the parkinsonism in the original PARK8 family , 2005, Annals of neurology.

[110]  Mathias Toft,et al.  Clinical features of LRRK2‐associated Parkinson's disease in central Norway , 2005, Annals of neurology.

[111]  M. Albrecht.  LRRK2 mutations and Parkinsonism , 2005, The Lancet.

[112]  Mathias Toft,et al.  LRRK2 mutations and Parkinsonism , 2005, The Lancet.

[113]  Timothy Lynch,et al.  Identification of a novel LRRK2 mutation linked to autosomal dominant parkinsonism: evidence of a common founder across European populations. , 2005, American journal of human genetics.

[114]  A. Sáenz,et al.  Familial Parkinson's disease: Clinical and genetic analysis of four Basque families , 2005, Annals of neurology.

[115]  J. Tschopp,et al.  The RIP kinases: crucial integrators of cellular stress. , 2005, Trends in biochemical sciences.

[116]  Nicholas W Wood,et al.  A common LRRK2 mutation in idiopathic Parkinson's disease , 2005, The Lancet.

[117]  Vincenzo Bonifati,et al.  A frequent LRRK2 gene mutation associated with autosomal dominant Parkinson's disease , 2005, The Lancet.

[118]  Thomas Meitinger,et al.  Mutations in LRRK2 Cause Autosomal-Dominant Parkinsonism with Pleomorphic Pathology , 2004, Neuron.

[119]  Andrew Lees,et al.  Cloning of the Gene Containing Mutations that Cause PARK8-Linked Parkinson's Disease , 2004, Neuron.

[120]  Regina Katzenschlager,et al.  Olfaction and Parkinson's syndromes: its role in differential diagnosis , 2004, Current opinion in neurology.

[121]  N. Pedersen,et al.  No evidence for heritability of Parkinson disease in Swedish twins , 2004, Neurology.

[122]  D W Dickson,et al.  Autosomal dominant parkinsonism associated with variable synuclein and tau pathology , 2004, Neurology.

[123]  Bertram Müller-Myhsok,et al.  The PARK8 locus in autosomal dominant parkinsonism: confirmation of linkage and further delineation of the disease-containing interval. , 2004, American journal of human genetics.

[124]  Donato A Di Monte,et al.  The environment and Parkinson's disease: is the nigrostriatal system preferentially targeted by neurotoxins? , 2003, The Lancet Neurology.

[125]  C. Tanner.  Is the cause of Parkinson's disease environmental or hereditary? Evidence from twin studies. , 2003, Advances in neurology.

[126]  D. Soll,et al.  A novel cGMP signalling pathway mediating myosin phosphorylation and chemotaxis in Dictyostelium , 2002, EMBO Journal.

[127]  A. Bretscher,et al.  ERM proteins and merlin: integrators at the cell cortex , 2002, Nature Reviews Molecular Cell Biology.

[128]  S. Tsuji,et al.  A new locus for Parkinson's disease (PARK8) maps to chromosome 12p11.2–q13.1 , 2002, Annals of neurology.

[129]  M. Farrer,et al.  Pathology of PD in monozygotic twins with a 20-year discordance interval , 2001, Neurology.

[130]  M. Hamida,et al.  Clinical and genetic study of familial Parkinson’s disease in Tunisia , 2000, Neurology.

[131]  A. Lees,et al.  What features improve the accuracy of clinical diagnosis in Parkinson's disease , 1992, Neurology.